Dapagliflozin offers intermediate value for patients who have heart failure with reduced ejection fraction (HFrEF), regardless of diabetes or health-impairment status, according to a recent economic analysis. “[G]iven evidence of clinical benefit and economic value, focus should be on increasing therapy rates among patients who have HFrEF with and without diabetes,” the authors wrote in JAMA Cardiology.
Slomski A. Is Dapagliflozin Cost-effective for Treating Heart Failure? JAMA. 2021;326(5):378. doi:10.1001/jama.2021.12116
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: